-+ 0.00%
-+ 0.00%
-+ 0.00%
Corcept Reports Eight-Year Response to Relacorilant Combination in Vulvar Cancer Patient
Share
Listen to the news
Corcept Reports Eight-Year Response to Relacorilant Combination in Vulvar Cancer Patient
  • Corcept Therapeutics announced a published case report in ESMO Rare Cancers describing sustained disease control with relacorilant combined with nab-paclitaxel.
  • The heavily pretreated patient with metastatic vulvar cancer benefited for approximately eight years, substantially longer than with her prior taxane-based treatment.
  • As of July 2026, the patient remained in good health on treatment, with stable disease and no new lesions.
  • The single-patient findings are not representative of the broader population; relacorilant is not approved for metastatic vulvar cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20261116644531) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending